Targeting Right Ventricle in Pulmonary Hypertension Gilead
Status:
Completed
Trial end date:
2018-01-01
Target enrollment:
Participant gender:
Summary
This study is looking to see if giving ranolazine to subjects on stable pulmonary
hypertension therapies but with right ventricular dysfunction (RVEF <45%) will improve their
health by improving right ventricular (RV) function.
Phase:
Phase 4
Details
Lead Sponsor:
University of Pennsylvania
Collaborators:
Brigham and Women's Hospital Gilead Sciences University of Maryland University of Maryland, College Park